Navigation Links
Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
Date:6/22/2013

arge cardiovascular outcome trial.

About Diabetes
Approximately 25.8 million Americans2 and an estimated 371 million people worldwide3 have type 1 or type 2 diabetes. T2D is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.2 Diabetes is a chronic condition that occurs when the body does not properly produce or use the hormone insulin4. Diabetes was estimated to cost the U.S. $245 billion in direct medical costs and reduced productivity in 2012.5

Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centers on three compounds representing several of the largest diabetes treatment classes. This alliance leverages the companies' strengths as two of the world's leading pharmaceutical companies, combining Boehringer Ingelheim's solid track record of research-driven innovation and Lilly's innovative research, experience, and pioneering history in diabetes. By joining forces, the companies demonstrate commitment in the care of people with diabetes and stand together to focus on patient needs. Find out more about the alliance at www.boehringer-ingelheim.com or www.lilly.com.

About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned co
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
2. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
3. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
4. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
6. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
7. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
8. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
9. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
10. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
11. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MYERS, Fla. , Jan. 23, 2015  Today the ... of Novartis, Bexsero® for the prevention of serogroup ... 25. Bexsero and Pfizer,s vaccine Trumenba®, which received FDA ... helping prevent this devastating disease. "I ...
(Date:1/23/2015)... to Fight Chronic Disease (PFCD) released a public opinion poll of ... study analyzing the impact of increased cost sharing on patient adherence ... educate policy makers and the public on the costs of chronic ... the Iowa healthcare exchange could be improved ...
(Date:1/23/2015)... than a third of reproductive-aged women enrolled in Medicaid, and ... a prescription for an opioid pain medication each year during ... Mortality Weekly Report (MMWR). Opioids are typically ... pain.  They are also found in some prescription cough medications. ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... and Efficacy Data Presented at 1st IASLC-ESMO European Lung ... ... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused,on ... trial of picoplatin confirming previously announced interim,results showing a survival benefit ...
... Replidyne, Inc.,(Nasdaq: RDYN ) announced today that ... clinical trial testing faropenem medoxomil,(faropenem) in patients with ... action to conserve its cash assets and support,initiatives ... programs., The AECB study is one in ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 2Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 3Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 4Replidyne Discontinues Phase III Trial 2Replidyne Discontinues Phase III Trial 3
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put ... muscle by up to 30lbs in less than 12 weeks ... Stan Stevenson, prompting an investigative review. , “Our Incredible ... diet formula that allows the body to pack on a ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... eliminate rabies in dogs//., ,The vaccine, in the ... scientists at the High Security Animal Disease Laboratory (HSADL)., ... stray dogs due to its artificial taste enhancers - like ... inside the dog's mouth, the capsule bursts and the medicine ...
... Mount Sinai School of Medicine have just developed an ... microdomains of leukocytes// or white blood cells. Microdomains are ... which receptors and signaling molecules accumulate during cell activation. ... white blood cell subsets and their forming microdomains in ...
... An Indian American fitness guru has created a fusion of ... in the United States//. , ,Sarina Jain, also ... Bhangra' and is credited with the introduction of Bhangra, the ... ,Jain holds her aerobic classes all over the US, ...
... are increasingly at the risk of becoming infected with ... active TB disease//, according to an analysis of previously ... ,About one-third of the world’s population is infected with ... is usually rendered inactive by the immune system, according ...
... A recent report published by the Center for Science in ... served in popular hotels// are very high in calories. The ... increased a lot which is leading to many health issues ... the food and its nutritional information enable the consumer to ...
... Compendium of Health Statistics published by the Office of Health ... method. This is costing the NHS twice as much as ... the deliveries by C section have increased to 23.2%. There ... 1995 to 2006. There is an increase of emergency C ...
Cached Medicine News:Health News:New Imaging Technique Tracks Traffic Patterns of White Blood Cells 2Health News:Susceptibility to TB is High Among the Smokers 2
The convenience of disposable type lenses available in a wide variety of options. Recommended replacement schedule: one week for extended wear, two weeks for daily wear....
Acuvue2 is designed to be worn as a two-week daily wear lens (which means you take the lenses out each night). It can also be worn as a one-week extended wear lens (which means you can sleep in them)...
... content spherical soft lens manufactured using ... for use in the correction of ... wear basis. The increased mid-peripheral thickness ... good handling across the power range. ...
... An easy-to-fit low water content spherical soft ... III" or cast molding technology, and designed ... and hyperopia on a daily wear or ... provides good oxygen transmission, while an increased ...
Medicine Products: